Skip to main content
U.S. flag

An official website of the United States government

Here’s how you know

Dot gov

The .gov means it’s official.

Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.

The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

    CMS.gov Centers for Medicare & Medicaid Services CMS.gov Centers for Medicare & Medicaid Services opens in new window
    CMS.gov Centers for Medicare & Medicaid Services
    Centers for Medicare & Medicaid Services

    Main header

    • About Us
    • Newsroom
    • Data & Research
    MCD
    Medicare Coverage Database
    • Advanced Search
    • Indexes
    • Reports
    • Downloads
    • National Coverage
      • National Coverage Analyses (NCAs)
        • Open NCAs
        • Closed NCAs
      • Coding Analyses for Labs (CALs)
        • Closed CALs
      • National Coverage Determinations (NCDs)
        • NCDs Listed Alphabetically
        • NCDs by Chapter/Section
        • Lab NCDs
      • Meetings & Assessments
        • MEDCAC Meetings
        • Technology Assessments
      • Medicare Coverage Documents
        • CMS Solicitation of Public Comments.
        • Compendia
        • Expedited Process to Remove National Coverage Determinations
        • Guidance Documents
        • National Benefit Category Analyses
        • Potential National Coverage Determination (NCD) Topics
    • Local Coverage
      • Local Coverage Determinations (LCDs)
        • LCDs by Contractor
        • LCDs by State
        • LCDs Listed Alphabetically
      • Articles
        • Articles by Contractor
        • Articles by State
        • Articles Listed Alphabetically
      • Contacts
        • All Contacts Listed Alphabetically
        • Contacts for Part A - Medicare Administrative Contractor (MAC - Part A)
        • Contacts for Part B - Medicare Administrative Contractor (MAC - Part B)
        • Contacts for Durable Medical Equipment Medicare Administrative Contractor (DME MAC)
        • Contacts for Home Health & Hospice (HHH)
    • National Coverage
      • What's New Report
      • Annual Report
    • Local Coverage
      • What's New Report
      • LCD Status Report
      • Proposed LCD Status Report
      • LCD Last Updated Report
      • Article Status Report
      • SAD Exclusion List Report
    0
    • Help & Resources
    • Page Help opens in new window
    • Contact Us

    Try the new Search!

    The Redesigned Search is faster and easier to use!

    Advanced Search will be removed on April 30, 2021. Learn More

    MCD

    Back to National Coverage Determinations (NCDs) Alphabetical Index

    MEDCAC Meeting 7/20/2016 - Lower Extremity Chronic Venous Disease

    Select the Print Complete Record, Add to Basket or Email Record Buttons to print the record, to add it to your basket or to email the record.
    • Expand All All sections on the page are Expanded
    • Collapse All All sections on the page are Collapsed

    Expand/Collapse the Issue section Issue

    On July 20, 2016, the Centers for Medicare & Medicaid Services (CMS) will convene a panel of the Medicare Evidence Development and Coverage Advisory Committee (MEDCAC).  The MEDCAC panel will examine the scientific evidence underpinning the benefit and risk of existing lower extremity chronic venous disease treatments that aim to improve health outcomes in the Medicare population.  This meeting will also identify evidence gaps that exist related to lower extremity chronic venous disease.

    Clinical outcomes of interest to the Medicare program include: reduction in pain; reduction in edema; improvement in functional capacity; improvement in quality of life; avoidance of acute and chronic venous thromboembolism; avoidance of chronic thromboembolic pulmonary hypertension; avoidance of initial venous skin ulceration and recurrent ulceration; improvement in wound healing; reduction in all-cause mortality; and avoidance of repeat interventions and harms from the interventions.   

    By voting on specific questions, and by their discussions, MEDCAC panel members will advise CMS about the extent to which it may wish to use existing evidence as the basis for any future determinations about Medicare coverage for interventions related to lower extremity peripheral venous disease.  MEDCAC panels do not make coverage determinations, but CMS often benefits from their advice.

    Expand/Collapse the Actions Taken section Actions Taken

    May 6, 2016

    CMS posts MEDCAC meeting announcement and questions to panel.

    July 13, 2016

    Posted agenda, roster and speakers list for meeting.

    Also posted presentations (A-L, M-Z) and written comments.

    July 22, 2016

    Posted scoresheet from meeting.

    September 6, 2016

    Posted minutes and transcript from meeting


    • Webcast of meeting
    • Registration
    • Information about visiting CMS
    • Driving directions to CMS
    • Recommended hotels

    Expand/Collapse the Agenda section Agenda

    Federal Register Notice
    Agenda
    Medicare Evidence Development & Coverage Advisory Committee
    July 20, 2016
    7:30 AM – 4:30 PM
        CMS Auditorium 
      

    Rita Redberg, MD, Committee Chair
    Art Sedrakyan, MD, Acting Committee Vice Chair
    Lori Ashby, MA, Director, Division of Medical and Surgical Services, Coverage and Analysis Group
    Maria Ellis, Executive Secretary


    7:30 – 8:00 AM

    Registration

    8:00 – 8:15 AM

    Opening Remarks - Maria Ellis/Lori Ashby, MA/Rita Redberg, MD

    8:15 - 8:25 AM

    CMS Presentation & Voting Questions – Jyme Schafer, MD, MPH

    8:25 – 8:45 AM

    Matthew Allison, MD, MPH, FAHA, Professor, Department of Family Medicine and Public Health, University of California San Diego

    8:45 – 9:35 AM

    TA Presentation:  Schuyler Jones, MD, Lead Clinical Investigator and Sreekanth Vemulapalli, MD, Clinical Expert, Duke University Medical Center

    9:35 – 9:55 AM 

    Thomas W. Wakefield, MD, Stanley Professor of Surgery, Section of Vascular Surgery, University of Michigan, Director, Samuel and Jean Frankel Cardiovascular Center, University of Michigan Health System

    9:55 – 10:05 AM 

    Fedor Lurie, MD, PhD, RPVI, President, American Venous Forum Foundation, Associate Director, Jobst Vascular Institute, Adjunct Research Professor, Division of Vascular Surgery, University of Michigan  

    10:05 – 10:15 AM  

    BREAK

    10:15 – 11:50 AM

    Scheduled Public Comments

    (Refer to Speaker List)


    Public attendees, who have contacted the executive secretary prior to the meeting, will address the panel and present information relevant to the agenda. Speakers are asked to state whether or not they have any financial involvement with manufacturers of any products being discussed or with their competitors and who funded their travel to this meeting.


    11:50 – 12:00 AM

    Open Public Comments

    Public Attendees who wish to address the panel will be given that opportunity

    12:00 - 1:00 PM

    LUNCH (on your own)

    1:00 – 2:00 PM

    Questions to Presenters

    2:00 – 3:00 PM

    Initial Open Panel Discussion: Dr. Redberg

    3:00 – 4:00 PM

    Formal Remarks and Voting Questions

    The Chairperson will ask each panel member to state his or her position on the voting questions.

    4:00 – 4:20 PM

    Final Open Panel Discussion: Dr. Redberg

    4:20 – 4:30 PM

    Closing Remarks/Adjournment: Lori Ashby & Dr. Redberg

    Expand/Collapse the Minutes section Minutes

    Download meeting minutes.

    Expand/Collapse the Panel Voting Questions section Panel Voting Questions

    Download scoresheet.

    Medicare Evidence Development & Coverage Advisory Committee (MEDCAC)
    Lower Extremity Chronic Venous Disease
    July 20, 2016

    This MEDCAC meeting will examine the scientific evidence underpinning the benefit and risk of existing lower extremity chronic venous disease interventions that aim to improve health outcomes in the Medicare population. This meeting will also identify evidence gaps that exist related to lower extremity chronic venous disease. Lower extremity chronic venous disease is distinct from lower extremity peripheral artery disease as it is characterized by a different pathophysiology, epidemiology, set of clinical manifestations, and outcomes. Lower extremity chronic venous disease includes heterogeneous disorders that encompasses a variety of primary etiologies. Nevertheless, common to most of these venous conditions is a permanent alteration in venous structure and function, which leads to altered venous hemodynamics.

    Causes of altered venous blood flow include venous dilation and venous valvular reflux (venous valvular incompetence or “chronic venous insufficiency”) or venous obstruction (from prior venous thrombosis or mechanical compression).  Patients with any of these venous structural alterations may be asymptomatic or symptomatic, suffering from mild pain to severe discomfort, with or without edema.  Chronic venous disease can lead to major decrements in quality of life, and be associated with quality-of-life altering physical stigmata, including telangiectasias and varicose veins.  Venous obstruction, venous insufficiency, and post-thrombotic syndrome patients may suffer from significant dependent edema and loss of ambulatory function.  When venous insufficiency is associated with untreated (sustained) venous hypertension, the skin may be permanently damaged with initial and recurrent skin ulceration.

    Existing therapies to improve outcomes for individuals with lower extremity chronic venous disease are grouped into four main categories: medical therapy, lifestyle interventions (including exercise, smoking cessation, and weight reduction), mechanical compression therapies (support garments, bandaging and pneumatic compressive devices), and invasive procedures (endovascular techniques including venous angioplasty, stenting and ablation; and surgical interventions, including venous thrombectomy, venous bypass, venous ligation, and venous excision).

    Clinical outcomes of interest to the Medicare program include: reduction in pain; reduction in edema; improvement in functional capacity; improvement in quality of life; avoidance of acute and chronic venous thromboembolism; avoidance of chronic thromboembolic pulmonary hypertension; avoidance of initial venous skin ulceration and recurrent ulceration; improvement in wound healing; reduction in all-cause mortality; and avoidance of repeat interventions and harms from the interventions.

    Voting Questions

    For each voting question, please use the following scale identifying your level of confidence - with a score of 1 being low or no confidence and 5 representing high confidence.

    1      —      2      —      3      —      4     —      5
    Low                   Intermediate                      High
    Confidence                                            Confidence

    1. For adults with varicose veins and/or other clinical symptoms or signs of chronic venous insufficiency, how confident are you that there is sufficient evidence for an intervention that improves:
      1. Immediate/near-term health outcomes in patients presenting with symptoms?  In patients presenting without symptoms but with physical signs?
      2. Long-term health outcomes in patients presenting with symptoms?  In patients presenting without symptoms but with signs?


    Discussion:

    • If intermediate confidence (≥ 2.5), please identify the specific intervention(s) that are associated with evidence-based clinical benefit and identify the associated beneficial outcome(s).
    • Considering the heterogeneity of the Medicare population, discuss for which subgroups of the Medicare population the evidence demonstrates likely benefit or which subgroups are not likely to benefit from intervention.


    1. For adults with chronic venous thrombosis and venous obstruction (including individuals with post-thrombotic syndrome), how confident are you that there is sufficient evidence for an intervention that improves:
      1. Immediate/near-term health outcomes in patients presenting with symptoms?  In patients presenting without symptoms but with signs?
      2. Long-term health outcomes in patients presenting with symptoms?  In patients presenting without symptoms but with signs?


    Discussion:

    • If intermediate confidence (≥ 2.5), please identify the specific intervention(s) that are associated with evidence-based clinical benefit and identify the associated beneficial outcome(s).
    • Considering the heterogeneity of the Medicare population, discuss for which subgroups of the Medicare population the evidence demonstrates likely benefit or which subgroups are not likely to benefit from intervention.
      1. Immediate/near-term health outcomes?
      2. Long-term health outcomes?


    Additional Discussion Topics

    1. Discuss important venous disease evidence gaps that have not been previously or sufficiently addressed.


    2. Discuss any current venous disease treatment disparities and how they may affect the health outcomes of Medicare beneficiaries.


    3. Discuss any mechanisms that might be supported by CMS that would more quickly generate an improved evidence base that would underpin improved care for the Medicare population affected by lower extremity chronic venous diseases.

    Table 1. Definitions of Terms

    Term Definition
    Venous obstruction Defined as partial or complete blockage of venous flow in any venous segment; can result from internal blockage (e.g., thrombosis) or external compression of the vein
    Venous reflux Used to describe any retrograde venous flow in any venous segment; typically classified as (a) primary/idiopathic, (b) secondary (typically due to trauma, thrombosis, or mechanical/chemical/thermal etiologies), or (c) congenital
    Venous thrombosis Defined as the formation of a blood clot in any segment of the venous system; typically classified as deep or superficial
    Chronic venous insufficiency or incompetence (CVI) Reserved for advanced venous disease, indicated by C3-C6 on the CEAP classification, and defined as morphological abnormalities of the venous system that lead to symptoms/signs (specifically, moderate-severe LE edema, skin changes, and/or venous ulcers)
    Post-thrombotic syndrome Describes chronic venous symptoms and/or signs that occur as a result of DVT and its sequelae

    Abbreviations:

    CEAP = Clinical, Etiologic, Anatomic, Pathophysiologic
    DVT = deep vein thrombosis
    LE = lower extremity

    Expand/Collapse the Contact Information section Contact Information

    Lori Ashby
    lori.ashby@cms.hhs.gov

    Jyme Schafer, MD, MPH

    Expand/Collapse the Other Material section Other Material

    Transcript 1

    Expand/Collapse the Roster section Roster

    MEDCAC Roster

    Committee Chair

    Rita Redberg, MD, MSC
    Professor of Medicine
    UCSF School of Medicine
    Division of Cardiology
    University of California, San Francisco Medical Center

    Committee Acting Vice Chair

    Art Sedrakyan, MD, PhD
    Professor and Director
    Patient Centered Comparative
    Outcomes Research Program
    Weill Cornell Medical School

    MEDCAC Members

    Doug Campos-Outcalt, MD, MPA
    Medical Director
    Mercy Care Plan

    John Jeffrey Carr, MD
    Professor of Radiology
    Biomedical Informatics and Cardiovascular Medicine
    Vanderbilt University

    Aloysius B. Cuyjet, MD, MPH
    Medical Director
    HealthCare Partners, IPA

    Peter F. Lawrence, MD
    Chief of Vascular Surgeon
    University of California, Los Angeles

    Roger J. Lewis, MD, PhD, FACEP
    Professor and Vice Chair, Academic Affairs
    Department of Emergency Medicine
    Harbor-UCLA Medical Center

    Sandra J. Lewis, MD, FACC
    Clinical Associate Professor of Medicine
    Oregon Health and Science University in Portland
    Director, Research and Prevention
    Northwest Cardiovascular Institute

    Marcel Salive, MD, MPH
    Medical Officer
    National Institute on Aging
    National Institute of Health

    Julie A. Swain, MD
    Vice Chair for Clinical Performance
    Director of Clinical Research
    Department of Cardiovascular Surgery
    Icahn School of Medicine at Mount Sinai
    New York City
    Director, Center for Medical Devices (CMeD) at Mount Sinai Heart

    Due to unforeseen circumstances, Dr. Swain is unable to attend the meeting

    Diana Zuckerman, PhD
    President
    National Center for Health Research
    Cancer Prevention and Treatment Fund

    Industry Representative

    Leslie Wise
    Vice President
    Global Healthcare Economics

    Guest Panel Members

    Teresa L. Carman, MD
    Director
    Vascular Medicine
    University Hospitals Case Medical Center

    Anthony J. Comerota, MD, FACS, FACC
    Jobst Vascular Institute
    Toledo, Ohio
    Adjunct Professor of Surgery
    University of Michigan

    Invited Guest Speakers

    Matthew Allison, MD, MPH, RPVI
    Professor
    Family Medicine and Public Health
    University of California San Diego
    Director, Vascular Laboratory
    Veterans Affairs San Diego Healthcare System

    Fedor Lurie, MD, PhD, RPVI
    President
    American Venous Forum Foundation
    Associate Director
    Jobst Vascular Institute
    Adjunct Research Professor
    Division of Vascular Surgery
    University of Michigan

    Thomas Wakefield, MD
    Section Head
    Stanley Professor of Vascular Surgery
    Director
    Samuel & Jean Frankel Cardiovascular Center
    University of Michigan

    CMS Liaison

    Lori Ashby, MA
    Director
    Division of Medical and Surgical Services
    Coverage and Analysis Group

    Executive Secretary

    Maria Ellis
    Coverage and Analysis Group

    Expand/Collapse the Speakers List section Speakers List

    Medicare Evidence Development & Coverage Advisory Committee
    July 20, 2016

    SPEAKER LIST


    *4 MINUTES PER SPEAKER*

    • Oscar M. Alvarez, PhD, CCT, FAPWCA, Director, University Wound Care Centers and Professor, Department of Medicine, New York Medical College
    • Marlin W. Schul, MD, RVT, FACP, Owner, Indiana Vascular Associates, LLC dba Lafayette Regional Vein & Laser Center – Representing: ACP PRO Venous Registry
    • K. Francis Lee, MD, PC, Founder and Medical Director of Advanced Vein Care Center – No PowerPoint
    • Nick Morrison, MD, FACPh, FACS, RPhS, President, International Union of Phlebology - Representing: United States Compression Alliance
    • Peter Gloviczki, MD, The Joe M. and Ruth Roberts Professor of Surgery, Chair Emeritus, Division of Vascular and Endovascular Surgery, Director Emeritus, Gonda Vascular Center, Mayo Clinic
    • Cynthia K. Shortell, MD, Professor of Surgery, Duke University
    • Peter Henke, MD, Leland Ira Doan Professor of Surgery, Section of Vascular Surgery, University of Michigan
    • Michael C. Dalsing, MD, Professor of Surgery, Division of Vascular Surgery, Indiana University School of Medicine – Representing: The Society for Vascular Surgery and The American Venous Forum
    • Thomas F. O’Donnell, Jr., MD, Benjamin Andrews Emeritus Professor of Surgery, Tufts University School of Medicine, Senior Surgeon Tufts Medical Center
    • Brajesh K. Lal, MD, Professor of Surgery, Division of Vascular Surgery, University of Maryland School of Medicine – strong>Representing: The Society for Vascular Surgery and The American Venous Forum
    • Janice Smiell, MD, Chief Medical Officer, Alliqua BioMedical, Inc. - Due to unforeseen circumstances, she was unable to attend the meeting.
    • Suman Rathbun, MD, MS, FSVM, FACP, Professor of Medicine, Director, Vascular Medicine, University of Oklahoma Health Sciences Center
    • Mark H. Meissner, MD, Professor of Surgery, University of Washington School of Medicine
    • Suresh Vedantham, MD, President-Elect, Society of Interventional Radiology, Principal Investigator, ATTRACT & C-TRACT Trials, Professor of Radiology & Surgery, Mallinckrodt Institute of Radiology, Washington University in St. Louis
    • Gregory Piazza, MD, MS, FACC, FSVM, Cardiovascular Medicine Division, Brigham and Women’s Hospital
    • Joshua A. Beckman, MD, Director, Section of Vascular Medicine, Vanderbilt University Medical Center, Chair, PVD Council, American Heart Association
    • Sean P. Lyden MD, Chairman, Vascular Surgery, Cleveland Clinic - Representing: VIVA Physicians
    • Mark Turco, MD, Medical Director, Aortic and Peripheral Vascular, Medtronic
    • Mark J. Garcia, MD, MS, FSIA, EndoVascular Consultants, LLC
    • Gary Gibbons, MD, Medical Director, South Shore Hospital, Center for Wound Healing, and Board Member, Association for the Advancement of Wound Care
    • Eric Lullove DPM, CWS, FACCWS, Medical Director, West Boca Center for Wound Healing, and Board Member, Association for the Advancement of Wound Care
    • R. Daniel Davis, DPM, President, American Podiatric Medical Association
    • Jim Harmon, Vice President of Global Market Access, BTG International, Inc.
    • Caroline Fie, MD, Executive Director of the US Wound Registry (USWR)

    Expand/Collapse the Technology Assessment section Technology Assessment

    http://www.ahrq.gov/research/findings/ta/index.html
    Footer Links
    • Submit Feedback/Ask a Question
    30

    Get email updates

    Sign up to get the latest information about your choice of CMS topics in your inbox. Also, you can decide how often you want to get updates.

    CMS & HHS WEBSITES

    • Medicare.govopens in new window
    • MyMedicare.govopens in new window
    • Medicaid.govopens in new window
    • InsureKidsNow.govopens in new window
    • HealthCare.govopens in new window
    • HHS.govopens in new window

    HELPFUL LINKS

    • Acronyms
    • Archive
    • Contacts
    • Glossary
    • Privacy policy

    RSS FEEDS

    • Newsroom
    • Blog
    • Podcast
    U.S. Department of Health & Human Servicesopens in new window Centers for Medicare & Medicaid Servicesopens in new window

    A federal government website managed and paid for by the U.S. Centers for Medicare & Medicaid Services.

    7500 Security Boulevard, Baltimore, MD 21244

    opens in new window opens in new window opens in new window

    TOOLS

    • Web policiesopens in new window
    • Plain languageopens in new window
    • No Fear Actopens in new window
    • Freedom of Information Actopens in new window
    • Inspector Generalopens in new window